MD4898B1 - Compoziţie, în particular o compoziţie farmaceutică preventivă şi curativă pe bază de peroxometalat - Google Patents
Compoziţie, în particular o compoziţie farmaceutică preventivă şi curativă pe bază de peroxometalat Download PDFInfo
- Publication number
- MD4898B1 MD4898B1 MDA20190018A MD20190018A MD4898B1 MD 4898 B1 MD4898 B1 MD 4898B1 MD A20190018 A MDA20190018 A MD A20190018A MD 20190018 A MD20190018 A MD 20190018A MD 4898 B1 MD4898 B1 MD 4898B1
- Authority
- MD
- Moldova
- Prior art keywords
- composition
- peroxometallate
- preventive
- mixture
- metal
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000003449 preventive effect Effects 0.000 title 1
- 239000010931 gold Substances 0.000 abstract 2
- 229910052751 metal Inorganic materials 0.000 abstract 2
- 239000002184 metal Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 241000700586 Herpesviridae Species 0.000 abstract 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 239000002738 chelating agent Substances 0.000 abstract 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052737 gold Inorganic materials 0.000 abstract 1
- 229910052747 lanthanoid Inorganic materials 0.000 abstract 1
- 150000002602 lanthanoids Chemical class 0.000 abstract 1
- 229910052746 lanthanum Inorganic materials 0.000 abstract 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052750 molybdenum Inorganic materials 0.000 abstract 1
- 239000011733 molybdenum Substances 0.000 abstract 1
- 238000005502 peroxidation Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 abstract 1
- 229910052721 tungsten Inorganic materials 0.000 abstract 1
- 239000010937 tungsten Substances 0.000 abstract 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Invenţia se referă la un amestec sau o compoziţie, de preferinţă terapeutic activă administrată topic, care conţine cel puţin o sare a unui metal, unde metalul este selectat dintre molibden (Mo), wolfram (W), vanadiu (V), aur (Au), o lantanidă, în particular lantan; cel puţin un agent de chelare; cel puţin o sursă de radicali de peroxidare; cel puţin un agent tampon; precum şi la compoziţii farmaceutice, formate din acest amestec sau conţinându-l, metode de producere şi aplicare a acestuia, şi anume pentru o metodă de tratament terapeutic a unei infecţii virale, în particular implicând un virus din familia Herpesviridae, sau ca un antiinflamator.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1652697A FR3049465B1 (fr) | 2016-03-29 | 2016-03-29 | Composition pharmaceutique preventive et curative a base de peroxometallate |
| PCT/IB2017/051797 WO2017168344A1 (fr) | 2016-03-29 | 2017-03-29 | Composition, notamment composition pharmaceutique préventive et curative, à base de peroxométallate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| MD20190018A2 MD20190018A2 (ro) | 2019-08-31 |
| MD4898B1 true MD4898B1 (ro) | 2024-08-31 |
| MD4898C1 MD4898C1 (ro) | 2025-03-31 |
Family
ID=56119576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20190018A MD4898C1 (ro) | 2016-03-29 | 2017-03-29 | Compoziţie, în particular o compoziţie farmaceutică preventivă şi curativă pe bază de peroxometalat |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10857179B2 (ro) |
| EP (1) | EP3435979B1 (ro) |
| JP (1) | JP7516006B2 (ro) |
| KR (1) | KR102345412B1 (ro) |
| CN (1) | CN109562062B (ro) |
| AU (1) | AU2017243946B2 (ro) |
| CA (1) | CA3019739A1 (ro) |
| CL (1) | CL2018002717A1 (ro) |
| CO (1) | CO2018011344A2 (ro) |
| EA (1) | EA038115B1 (ro) |
| FR (1) | FR3049465B1 (ro) |
| IL (1) | IL261982B2 (ro) |
| MA (1) | MA44950B1 (ro) |
| MD (1) | MD4898C1 (ro) |
| MX (1) | MX389086B (ro) |
| MY (1) | MY197527A (ro) |
| PE (1) | PE20190259A1 (ro) |
| PH (1) | PH12018502091A1 (ro) |
| SA (1) | SA518400119B1 (ro) |
| SG (1) | SG11201808651WA (ro) |
| TN (1) | TN2018000332A1 (ro) |
| WO (1) | WO2017168344A1 (ro) |
| ZA (2) | ZA201806489B (ro) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8933078B2 (en) | 2011-07-14 | 2015-01-13 | Research Cancer Institute Of America | Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances |
| FR3049465B1 (fr) * | 2016-03-29 | 2018-04-27 | Oxymo Technologies Inc. | Composition pharmaceutique preventive et curative a base de peroxometallate |
| WO2018157081A1 (en) | 2017-02-27 | 2018-08-30 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
| US11369585B2 (en) | 2017-03-17 | 2022-06-28 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
| US12213958B2 (en) | 2017-11-17 | 2025-02-04 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
| FR3110396B1 (fr) | 2020-05-20 | 2023-03-17 | M G B Pharma | Composition comprenant un composé ascorbo-camphorate métallique pour son utilisation dans le traitement des infections causées par herpèsvirus |
| WO2021262749A1 (en) * | 2020-06-26 | 2021-12-30 | Research Cancer Institute Of America | Compositions and methods for preventing and/or treating viral infection |
| WO2022215707A1 (ja) * | 2021-04-08 | 2022-10-13 | 日本特殊陶業株式会社 | セラミックス材料、圧粉体、焼結体、及び物品 |
| CN115246656B (zh) * | 2022-01-12 | 2023-07-25 | 青岛大学 | 一种氧化钼/铁纳米材料的制备方法及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0629191B2 (ja) * | 1984-09-04 | 1994-04-20 | 株式会社ポリトロニクス | 抗腫瘍剤、抗ウィルス剤 |
| JP2707252B2 (ja) * | 1987-08-03 | 1998-01-28 | 利博 山瀬 | 抗ウィルス剤 |
| JP3121859B2 (ja) * | 1991-05-31 | 2001-01-09 | 利博 山瀬 | 抗ウイルス剤 |
| JP4420997B2 (ja) * | 1999-02-08 | 2010-02-24 | 利博 山瀬 | 抗ウィルス剤 |
| FR2792500B1 (fr) | 1999-04-23 | 2004-05-21 | Internat Redox Dev | Composition aqueuse, notamment sous forme de gel, a base de ho2f , acides et ions metalliques, procede de preparation notamment quand lesdits ions sont ag2+ et utilisation dans le domaine de la desinfection et/ou du traitement de surface |
| US8232320B2 (en) * | 1999-04-28 | 2012-07-31 | The Regents Of The University Of Michigan | Antimicrobial nanoemulsion compositions and methods |
| WO2003103691A1 (en) * | 2001-06-07 | 2003-12-18 | Chiou Consulting, Inc. | Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions |
| FR2858086A1 (fr) * | 2003-07-23 | 2005-01-28 | France Telecom | Procede d'estimation de la pertinence d'un document par rapport a un concept |
| US7553805B2 (en) * | 2005-02-25 | 2009-06-30 | Solutions Biomed, Llc | Methods and compositions for treating viral, fungal, and bacterial infections |
| FR2932952A1 (fr) | 2008-06-26 | 2010-01-01 | Orbeco Inc | Composition aqueuse, notamment desinfectante, a base de h202 procede de fabrication et utilisation. |
| US20140314827A1 (en) * | 2013-04-18 | 2014-10-23 | Steven A. Melman | Antimicrobial compositions and uses therefor |
| EP2989054A2 (en) * | 2013-04-25 | 2016-03-02 | Cerion Enterprises, LLC. | Chelated nanoceria for the treatment of oxidative stress |
| FR3049465B1 (fr) * | 2016-03-29 | 2018-04-27 | Oxymo Technologies Inc. | Composition pharmaceutique preventive et curative a base de peroxometallate |
-
2016
- 2016-03-29 FR FR1652697A patent/FR3049465B1/fr active Active
-
2017
- 2017-03-29 AU AU2017243946A patent/AU2017243946B2/en active Active
- 2017-03-29 CN CN201780029434.6A patent/CN109562062B/zh active Active
- 2017-03-29 MY MYPI2018703547A patent/MY197527A/en unknown
- 2017-03-29 CA CA3019739A patent/CA3019739A1/fr active Pending
- 2017-03-29 SG SG11201808651WA patent/SG11201808651WA/en unknown
- 2017-03-29 WO PCT/IB2017/051797 patent/WO2017168344A1/fr not_active Ceased
- 2017-03-29 TN TNP/2018/000332A patent/TN2018000332A1/fr unknown
- 2017-03-29 US US16/089,757 patent/US10857179B2/en active Active
- 2017-03-29 MD MDA20190018A patent/MD4898C1/ro active IP Right Grant
- 2017-03-29 EA EA201891941A patent/EA038115B1/ru unknown
- 2017-03-29 PE PE2018001922A patent/PE20190259A1/es unknown
- 2017-03-29 JP JP2018551991A patent/JP7516006B2/ja active Active
- 2017-03-29 MA MA44950A patent/MA44950B1/fr unknown
- 2017-03-29 EP EP17714305.4A patent/EP3435979B1/fr active Active
- 2017-03-29 MX MX2018011968A patent/MX389086B/es unknown
- 2017-03-29 KR KR1020187031280A patent/KR102345412B1/ko active Active
-
2018
- 2018-09-25 CL CL2018002717A patent/CL2018002717A1/es unknown
- 2018-09-27 SA SA518400119A patent/SA518400119B1/ar unknown
- 2018-09-27 IL IL261982A patent/IL261982B2/en unknown
- 2018-09-28 ZA ZA2018/06489A patent/ZA201806489B/en unknown
- 2018-09-28 PH PH12018502091A patent/PH12018502091A1/en unknown
- 2018-10-23 CO CONC2018/0011344A patent/CO2018011344A2/es unknown
-
2019
- 2019-03-29 ZA ZA2019/02008A patent/ZA201902008B/en unknown
-
2020
- 2020-10-16 US US17/073,026 patent/US11944639B2/en active Active
-
2022
- 2022-11-08 US US18/053,609 patent/US12533377B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD4898B1 (ro) | Compoziţie, în particular o compoziţie farmaceutică preventivă şi curativă pe bază de peroxometalat | |
| ZA202500439B (en) | Therapeutic compounds for hiv virus infection | |
| MY209319A (en) | Compounds useful to treat influenza virus infections | |
| SA523441639B1 (ar) | مركبات بيريدو-تريازين البديلة واستخداماتها | |
| MX386782B (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| MX2021004182A (es) | Inhibidores macrocíclicos de endonucleasa de la gripe. | |
| EA202191239A1 (ru) | Соединения и их применение для лечения дефицита 1-антитрипсина | |
| MX388251B (es) | Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo. | |
| EA200702242A1 (ru) | Использование сульфонамидного соединения для улучшения фармакокинетики лекарственного средства | |
| CA3013473C (en) | Methods for treatment and prophylaxis of hiv and aids | |
| EA202191711A1 (ru) | Производные пиримидона в качестве селективных цитотоксических агентов против вич-инфицированных клеток | |
| ZA202308388B (en) | Nasal compositions comprising alcaftadine | |
| MX2024000043A (es) | Compuestos inhibidores de la caspasa-2. | |
| JOP20220045A1 (ar) | تركيبة صيدلانية مائية من جسم مضاد ANTI-PD1 برولجوليماب prolgolimab واستخدامها | |
| MX388699B (es) | Formas cristalinas de cabotegravir de sodio | |
| EA201890789A1 (ru) | Содержащая цинеол композиция для лечения заболеваний носа | |
| PL431336A1 (pl) | Lipopeptydy, kompozycja farmaceutyczna, kompozycja kosmetyczna oraz lipopeptydy do zastosowania jako lek | |
| EP1868639A4 (en) | METHOD OF USING IONIZATION RADIATION IN HIV INFECTION THERAPY | |
| PH12020500246A1 (en) | Pharmaceutical compositions | |
| PH12020050031B1 (en) | Methods and preparations of Mentha cordifolia in the treatment for Human Immunodeficiency Virus (HIV) infection | |
| NZ746685B2 (en) | Composition, in particular a preventive and curative pharmaceutical composition, made from peroxometallate | |
| MX2022002447A (es) | Composiciones y métodos para el tratamiento de la infección por influenza a. | |
| FR3094638B1 (fr) | Produit pour la prévention et le traitement de la cinétose | |
| NZ784982B2 (en) | Methods for treatment and prophylaxis of hiv and aids | |
| WO2016059647A3 (en) | Triaminotriazine picolinonitrile derivatives as potent reverse transcriptase inhibitor of hiv-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG4A | Patent for invention issued |